Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats

Koji Abe, Masahito Horiuchi, Kohji Yoshimura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effects of cholinergic and noradrenergic depletion, alone and in combination, on spatial memory and electroencephalogram (EEG) activity were investigated. Basal forebrain-lesioned rats exhibited a significant decrease in cortical choline acetyltransferase activity and spatial memory impairment. In the cortical EEG, the basal forebrain lesion induced EEG slowing such as an increase in delta power activity and a decrease in beta power activity. Noradrenergic depletion following a treatment with DSP-4 (N-2-(chloroethyl)-N-ethyl-2-bromobenzylamine) had no effect on cortical choline acetyltransferase activity and spatial memory, but it aggravated the cognitive impairment induced by the basal forebrain lesion. DSP-4 itself increased delta power activity in non-lesioned rats, whereas DSP-4 potentiated the EEG slowing induced by the basal forebrain lesions. Systemic administration of tetrahydroaminoacridine at 1 or 3 mg/kg, i.p., ameliorated the memory deficits and EEG slowing induced by the basal forebrain lesion. However, the drug could not attenuate the EEG slowing and memory impairment in rats that had received a combination of DSP-4 and basal forebrain lesion. These results suggest that noradrenergic depletion aggravated the EEG slowing and the spatial memory impairment induced by cholinergic dysfunction and may decrease the efficacy of an anticholinesterase agent in reversing the cortical cholinergic hypofunction.

Original languageEnglish
Pages (from-to)149-155
Number of pages7
JournalEuropean Journal of Pharmacology
Volume321
Issue number2
DOIs
Publication statusPublished - Feb 26 1997
Externally publishedYes

Fingerprint

Electroencephalography
Cholinergic Agents
Choline O-Acetyltransferase
Tacrine
Cholinesterase Inhibitors
Memory Disorders
DSP 4
Basal Forebrain
Spatial Memory
Pharmaceutical Preparations
Power (Psychology)

Keywords

  • Basal forebrain lesion
  • DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)
  • EEG (electroencephalogram)
  • Memory
  • Noradrenaline
  • Tetrahydroaminoacridine

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats. / Abe, Koji; Horiuchi, Masahito; Yoshimura, Kohji.

In: European Journal of Pharmacology, Vol. 321, No. 2, 26.02.1997, p. 149-155.

Research output: Contribution to journalArticle

Abe, Koji ; Horiuchi, Masahito ; Yoshimura, Kohji. / Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats. In: European Journal of Pharmacology. 1997 ; Vol. 321, No. 2. pp. 149-155.
@article{9f3f15dcacda42508d83d4f48544628a,
title = "Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats",
abstract = "The effects of cholinergic and noradrenergic depletion, alone and in combination, on spatial memory and electroencephalogram (EEG) activity were investigated. Basal forebrain-lesioned rats exhibited a significant decrease in cortical choline acetyltransferase activity and spatial memory impairment. In the cortical EEG, the basal forebrain lesion induced EEG slowing such as an increase in delta power activity and a decrease in beta power activity. Noradrenergic depletion following a treatment with DSP-4 (N-2-(chloroethyl)-N-ethyl-2-bromobenzylamine) had no effect on cortical choline acetyltransferase activity and spatial memory, but it aggravated the cognitive impairment induced by the basal forebrain lesion. DSP-4 itself increased delta power activity in non-lesioned rats, whereas DSP-4 potentiated the EEG slowing induced by the basal forebrain lesions. Systemic administration of tetrahydroaminoacridine at 1 or 3 mg/kg, i.p., ameliorated the memory deficits and EEG slowing induced by the basal forebrain lesion. However, the drug could not attenuate the EEG slowing and memory impairment in rats that had received a combination of DSP-4 and basal forebrain lesion. These results suggest that noradrenergic depletion aggravated the EEG slowing and the spatial memory impairment induced by cholinergic dysfunction and may decrease the efficacy of an anticholinesterase agent in reversing the cortical cholinergic hypofunction.",
keywords = "Basal forebrain lesion, DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine), EEG (electroencephalogram), Memory, Noradrenaline, Tetrahydroaminoacridine",
author = "Koji Abe and Masahito Horiuchi and Kohji Yoshimura",
year = "1997",
month = "2",
day = "26",
doi = "10.1016/S0014-2999(96)00934-X",
language = "English",
volume = "321",
pages = "149--155",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Potentiation by DSP-4 of EEG slowing and memory impairment in basal forebrain-lesioned rats

AU - Abe, Koji

AU - Horiuchi, Masahito

AU - Yoshimura, Kohji

PY - 1997/2/26

Y1 - 1997/2/26

N2 - The effects of cholinergic and noradrenergic depletion, alone and in combination, on spatial memory and electroencephalogram (EEG) activity were investigated. Basal forebrain-lesioned rats exhibited a significant decrease in cortical choline acetyltransferase activity and spatial memory impairment. In the cortical EEG, the basal forebrain lesion induced EEG slowing such as an increase in delta power activity and a decrease in beta power activity. Noradrenergic depletion following a treatment with DSP-4 (N-2-(chloroethyl)-N-ethyl-2-bromobenzylamine) had no effect on cortical choline acetyltransferase activity and spatial memory, but it aggravated the cognitive impairment induced by the basal forebrain lesion. DSP-4 itself increased delta power activity in non-lesioned rats, whereas DSP-4 potentiated the EEG slowing induced by the basal forebrain lesions. Systemic administration of tetrahydroaminoacridine at 1 or 3 mg/kg, i.p., ameliorated the memory deficits and EEG slowing induced by the basal forebrain lesion. However, the drug could not attenuate the EEG slowing and memory impairment in rats that had received a combination of DSP-4 and basal forebrain lesion. These results suggest that noradrenergic depletion aggravated the EEG slowing and the spatial memory impairment induced by cholinergic dysfunction and may decrease the efficacy of an anticholinesterase agent in reversing the cortical cholinergic hypofunction.

AB - The effects of cholinergic and noradrenergic depletion, alone and in combination, on spatial memory and electroencephalogram (EEG) activity were investigated. Basal forebrain-lesioned rats exhibited a significant decrease in cortical choline acetyltransferase activity and spatial memory impairment. In the cortical EEG, the basal forebrain lesion induced EEG slowing such as an increase in delta power activity and a decrease in beta power activity. Noradrenergic depletion following a treatment with DSP-4 (N-2-(chloroethyl)-N-ethyl-2-bromobenzylamine) had no effect on cortical choline acetyltransferase activity and spatial memory, but it aggravated the cognitive impairment induced by the basal forebrain lesion. DSP-4 itself increased delta power activity in non-lesioned rats, whereas DSP-4 potentiated the EEG slowing induced by the basal forebrain lesions. Systemic administration of tetrahydroaminoacridine at 1 or 3 mg/kg, i.p., ameliorated the memory deficits and EEG slowing induced by the basal forebrain lesion. However, the drug could not attenuate the EEG slowing and memory impairment in rats that had received a combination of DSP-4 and basal forebrain lesion. These results suggest that noradrenergic depletion aggravated the EEG slowing and the spatial memory impairment induced by cholinergic dysfunction and may decrease the efficacy of an anticholinesterase agent in reversing the cortical cholinergic hypofunction.

KW - Basal forebrain lesion

KW - DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)

KW - EEG (electroencephalogram)

KW - Memory

KW - Noradrenaline

KW - Tetrahydroaminoacridine

UR - http://www.scopus.com/inward/record.url?scp=0031053456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031053456&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(96)00934-X

DO - 10.1016/S0014-2999(96)00934-X

M3 - Article

C2 - 9063682

AN - SCOPUS:0031053456

VL - 321

SP - 149

EP - 155

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -